Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

17 terminated/withdrawn out of 17 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

16 withdrawn

Enrollment Performance

Analytics

N/A

10(58.8%)

Phase 1

7(41.2%)

17Total

N/A(10)

Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT01501461Not ApplicableWithdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome

Role: lead

NCT01559051Phase 1Withdrawn

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

Role: lead

NCT01739504Not ApplicableTerminated

Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.

Role: lead

NCT02087397Phase 1Withdrawn

Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction

Role: lead

NCT01453803Not ApplicableWithdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease

Role: lead

NCT01453751Not ApplicableWithdrawn

Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes

Role: lead

NCT02912169Phase 1Withdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease

Role: lead

NCT03272191Not ApplicableWithdrawn

Study to Assess Safety & Effects of Autologous ADSCs During Recovery Phase of ST-Elevation MI Effects of Autologous ADSC Implantation During Subacute Recovery Phase of ST-Elevation Myocardial Infarction

Role: lead

NCT01453764Not ApplicableWithdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

Role: lead

NCT01453829Phase 1Withdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke

Role: lead

NCT01502514Phase 1Withdrawn

Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure

Role: lead

NCT01974128Not ApplicableWithdrawn

Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction

Role: lead

NCT01502488Phase 1Withdrawn

Adipose Derived Stem Cell Therapy for Autism

Role: lead

NCT01453777Not ApplicableWithdrawn

Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain

Role: lead

NCT01453816Not ApplicableWithdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure

Role: lead

NCT01502501Not ApplicableWithdrawn

Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure

Role: lead

NCT02099500Phase 1Withdrawn

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

Role: lead

All 17 trials loaded